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Short title: FDG-PET/CT to diagnose ACC recurrence 
ABSTRACT 
Context The role of FDG PET/CT in the post-operative monitoring of patients with adrenocortical 
carcinoma (ACC) is still unclear. 
Objective To assess the accuracy of FDG PET/CT to diagnose ACC recurrence in a real world 
setting. 
Design/Methods Retrospective evaluation of data of 57 patients with presumed ACC recurrence at 
CT scan who underwent FDG PET/CT within a median time of 20 days. We compared the results 
of either FDG PET/CT or CT with a gold standard confirmation of recurrence (positive 
histopathology report of removed/biopsied lesions or radiological progression of target lesions at 
follow-up) to assess their diagnostic performance at different body sites to correctly categorize 
target lesions. We also assessed whether FDG PET/CT findings may be useful to inform the 
management strategy. 
Results In 48 patients with confirmed ACC recurrence, we found that FDG PET/CT had lower 
sensitivity than CT in diagnosing liver and lung recurrences of ACC. FDG PET/CT had higher 
specificity than CT in categorizing liver lesions. FDG PET/CT had a greater positive likelihood 
ratio than CT to identify liver and abdominal ACC recurrences. The management strategy was 
changed based on FDG PET-CT findings in 12 patients (21.1%). 
Conclusions The greater sensitivity of CT may be partly expected due the specific inclusion criteria 
of the study; however the greater specificity of FDG PET/CT was particularly useful in ruling out 
suspected ACC recurrences found by CT.  Thus, use of FDG PET/CT as a second-line test in the 
post-operative surveillance of ACC patients following CT finding of a potential recurrence may 
have a significant impact on patient management.  
INTRODUCTION 
Positron emission tomography (PET) with 
18
F-labeled 2-fluoro-2-deoxy-D-glucose (FDG) has an 
established role in the diagnostic approach of different types of tumors (1). More recently, PET/CT, 
a technique combining the anatomic and densitometric applications of CT and the functional and 
metabolic advantages of PET has been increasingly used in oncology (2, 3).  
Several studies have reported the effectiveness of FDG PET or PET/CT to differentiate benign 
from malignant adrenal tumors (4-11) but only few studies reported on the use of functional 
imaging techniques in the follow-up of adrenocortical carcinoma (ACC) (9-11). Thus, there is 
limited evidence that PET/CT may refine staging of ACC patients at initial diagnosis or during 
follow-up. This is not surprising due to the rarity of ACC that hampers progress in the development 
of management strategies (12, 13).  
It could be expected that PET/CT may provide useful and complementary information to CT in 
the detection of post-operative recurrences. In this clinical scenario, prompt detection of ACC re-
growth and precise definition of disease extension is of the utmost importance since surgery is a 
mainstay for treatment of ACC recurrence whenever it is done with radical intent (12, 14). 
However, repeating surgery is often technically demanding and not without risk for the patient 
while debulking does not offer much benefit (14); thus, an accurate pre-operative estimate of tumor 
burden is mandatory for appropriate selection of patients for surgery. However, no recommendation 
on the use of FDG-PET or PET/CT in the follow-up of patients following ACC removal, or patients 
with advanced ACC has been provided in recent reviews (15, 16).  
The objective of this work was to assess the accuracy of FDG PET/CT to diagnose ACC 
recurrence in a real world setting. Due to limited availability of the technique and cost issues, we 
have employed FDG PET/CT as a second-line test in patients with a potential ACC recurrence 
found by CT during post-surgical follow-up. We have retrospectively correlated FDG PET/CT and 
CT findings with histopathologic results for patients who underwent surgery or biopsy, or 
radiological progression of target lesions (RECIST criteria) for patients who were not operated on. 
SUBJECTS AND METHODS 
Patients 
Patient data were retrieved from the ACC database of the San Luigi Hospital, a tertiary referral 
center for patients with adrenal tumors. The database was established in 2001 with the development 
of a structured data form to collect comprehensive information of all patients with ACC treated at 
our center. Data of patients before 2011 were collected retrospectively, while in the following years 
data were input prospectively. Data were retrieved by trained medical personnel using specifically 
tailored data forms. For the purpose of this study, patients diagnosed between January 1998 and 
July 2012 were considered and follow-up for this study was closed on December 2013. The 
institutional ethics committee of our hospital approved the study, and all patients provided written 
informed consent. Selected patients underwent surgery either at the San Luigi Hospital or at other 
institutions.  
Inclusion criteria for the study were: age ≥18, pathologically confirmed diagnosis of ACC (in 50 
of 57 cases, diagnosis was made or confirmed by the pathologists of San Luigi Hospital), 
availability of pre-operative and post-operative computed tomography (CT) scans; ACC stage I-III 
at diagnosis, radical resection of primary tumor; confirmed diagnosis of ACC recurrence during 
follow-up of a previously tumor-free patient; availability of concomitant FDG PET/CT; complete 
follow-up information until death or end of the study period. Exclusion criteria were: incomplete 
tumor staging; ENSAT stage IV ACC; history of other previous/concomitant malignancies; 
incomplete resection; follow-up of less than 12 months or incomplete follow-up information, time 
elapsed between the index CT showing potential ACC recurrence and FDG PET/CT >60 days. 
We collected data on patients’ demographic and clinical characteristics, their tumor stage at 
diagnosis, hormonal workup, surgical approach, pathology report, adjuvant mitotane treatment, date 
and modality of recurrence, either the date and cause of death or the date of the last follow-up. 
Staging at diagnosis was based on imaging studies and corroborated by pathological findings at 
surgery. Staging was reported according to the ENSAT staging system (17). Radical resection was 
defined as no evidence of microscopic residual disease at pathological analysis. Follow-up visits, 
which included physical examination, routine laboratory and hormone evaluation, and cross-
sectional imaging of the chest and abdomen, were performed every 3 to 6 months until either 
disease progression or end of study occurred. For this study, suspected disease recurrence was 
defined as CT evidence of a possible new tumor site during follow-up (target lesion). The study 
included only patients with a presumed recurrence (target lesion) found on CT during follow-up. 
 
 
Imaging techniques 
FDG-PET images were acquired using the PET tomography Discovery ST (General Electric 
Medical Systems, Waukesha, Wisconsin, USA). Patients were asked to fast for at least six hours 
before the exam and a serum glucose level below 160 mg/dL was ensured. Image acquisition was 
performed after 60 minutes from intravenous administration of 222-370 MBq of FDG. Firstly an 
imaging field (CT scout view, with thickness of slices of 3.75 mm) was determined performing a 
CT scan (140 kV, tube current 80 mA/S) for both anatomical localization and calculation of 
attenuation correction. Then, PET data were acquired in a 3-dimensional mode from the pelvic floor 
to the skull basis in 6 to 7 bed positions. The acquisition time for PET was 2.5 minutes per bed 
position. Coronal, sagittal, and transverse data sets were reconstructed. Co-registered scans were 
displayed by using dedicated software (Advantage 4.2; GE Healthcare) and integrated FDG-
PET/CT data sets were prospectively evaluated in consensus by 3 nuclear medicine physicians. To 
qualify a PET imaging as positive, we used qualitative visual criteria following the guidelines 
of the European Association of Nuclear Medicine (18). The rationale is that there is no single 
lower limit of the intensity of FDG uptake for the detection of abnormal uptake within lesions 
as it depends on the degree of contrast between the tumor and its immediate surroundings. 
Thoraco-abdomino-pelvic CT scans were performed after intravenous iodinated contrast with multi-
slices CT whose thickness of slices varied from 0.5 to 1 mm.  Images were captured every 3 to 6 
months and were compared to the previous ones with a storage system (PACS). Lesions observed 
with CT and FDG PET/CT were analyzed by location and number, categorizing the findings 
according to the district (local, abdominal and peritoneal, liver, lung, bone, peritoneal lymph nodes, 
thoracic lymph nodes, other districts). Results of CT scans were also evaluated in consensus and 
compared to results of FDG PET/CT scans. All evaluations were blinded to the subsequent 
patient management. 
 
Confirmation of recurrence 
The gold standard test for categorizing any target lesion found in a given patient by 
imaging as ACC recurrence was one of the following: 1) positive histopathology report of 
removed, or biopsied, lesions; 2) radiological progression according to RECIST criteria of 
target lesions at follow-up when they were not removed or biopsied. 
 
 
 
 
Statistical analysis 
All statistical analyses were performed with Statistica (StatSoft) statistical software. Rates and 
proportions were calculated for categorical data and medians and ranges for continuous data. CT 
and FDG-PET results were compared with the gold standard test by means of 2 x 2 tables. For FDG 
PET/CT, we calculated sensitivity (SST = true positive/true positive + false negative), specificity 
(SPC = true negative/true negative + false positive), positive predictive value (PPV = TP/true 
positive + false positive), negative predictive value (NPV = true negative/true negative + false 
negative), positive likelihood ratio (LR+ = SST/1 - SPC) and negative likelihood ratio (LR- = 1 - 
SST/SPC). The diagnostic accuracy of CT and FDG-PET was analyzed by means of the chi-square 
test and Fisher’s exact test. Since the inclusion criteria of the study required positivity of the CT 
scan (detection of new lesion(s) during follow-up), we did not make a formal comparison of FDG 
PET/CT vs. CT to categorize patients as with or without ACC recurrence. However, we compared 
the results of either FDG PET/CT or CT with the gold standard confirmation of recurrence to assess 
their diagnostic performance at different body sites to correctly categorize target lesions as ACC 
recurrences. We also assessed whether FDG PET/CT findings may be useful to inform the 
management strategy. P values of less than 0.05 were considered to indicate statistical significance.  
RESULTS 
From the overall series of 214 ACC patients who underwent radical resection between 1998 and 
2012, 4 patients were excluded for concomitant malignancies, 3 were minors at the time of 
diagnosis, 62 patients did not recur during follow-up and 33 patients were lost to follow-up. In 57 of 
112 patients with presumed ACC recurrence, FDG PET/CT scan was done within a median time of 
20 days (range, 3-60 days) from the index CT suggesting disease recurrence and these patients 
formed the study cohort. Baseline characteristics of the patients are provided in table 1.  
In 40 out of 57 patients (70.2%) with one or more new target lesions at CT as marker of potential 
ACC recurrence, FDG PET/CT showed at least one significant focal uptake. Assessment of the 
uptake was performed in a qualitative or quantitative way via the Standardized Uptake Value 
(SUV). SUV of the target lesions ranged between 1.2 and 15.5, median 6.8. In 48 patients a 
definitive diagnosis of ACC recurrence was demonstrated by histological analysis of surgically 
removed lesions (23 cases), fine-needle biopsy (5 cases), or detection of radiological progression 
(RECIST criteria) at imaging follow-up of target lesions (20 cases). In the remaining 9 patients, 
ACC recurrence was not confirmed.  
When assessing concordance of CT and FDG PET/CT target lesions with confirmed ACC 
recurrences, we found that FDG PET/CT had lower sensitivity than CT in diagnosing liver and lung 
lesions as ACC recurrences (Table 2, Table 3); however, FDG PET/CT had higher specificity than 
CT in categorizing liver lesions. FDG PET/CT had a greater LR+ than CT to identify liver and 
abdominal ACC recurrences. FDG uptake of a liver lesion increases by 38 times the probability of 
being a true ACC recurrence. FDG uptake of an abdominal lesion increases by 52 times the 
probability of being a true ACC recurrence (Table 3). A list of false positive findings of PET/CT 
is given in table 4. 
In 26 patients (45.6%), CT and FDG PET/CT findings were superimposable (in 2 of them, both 
techniques had false positive results because local recurrence was finally excluded). When 
analyzing the 31 patients (54.4%) with discordant findings between the two imaging tests, CT 
showed a greater number of target lesions than FDG-PET/CT in 23 patients. Conversely, FDG 
PET/CT showed additional target lesions not found by CT in 4 patients. Finally, in 4 patients FDG 
PET/CT and CT showed two different target lesions (Figure 1). In 7 of the 23 patients with target 
lesions at CT without corresponding FDG uptakes, ACC recurrence was excluded (2 hepatic 
nodular hyperplasia, 2 unspecific pulmonary nodules, 2 post-surgical scars, 1 bone aspecific lesion). 
In the 8 patients with FDG PET/CT target lesions without corresponding CT findings, the additional 
lesions found by FDG PET/CT were demonstrated to be ACC recurrences.  
The management strategy was changed based on PET-CT findings in 12 patients (21.1%) (Table 
5). We did not treat 8 patients with CT lesions not confirmed by PET. The following work-up 
confirmed no ACC recurrence in 7 of them while a patient has to be considered as a false negative 
of PET/CT. We changed the treatment plan in 4 out of 8 patients who showed FDG PET/CT target 
lesions without corresponding CT findings. We gave a systemic treatment instead of surgery in 1 
patient and planned a more extensive surgery in 3 patients, in whom surgical and pathologic reports 
demonstrated the existence of multiple recurrence sites.  In the remaining 4 patients with discordant 
findings between techniques, we chose to base management on CT findings, but following 
investigations demonstrated the presence of ACC recurrence in the sites of FDG uptake.   
DISCUSSION 
The role of FDG PET/CT in the post-operative monitoring of ACC patients is yet to be 
established. A single study evaluated the role of FDG PET/CT to diagnose ACC recurrence and 
showed that PET was more sensitive than CT in detecting local recurrence, while CT was more 
sensitive in detecting small lung or peritoneal metastases (9). As a consequence, no formal 
recommendation on incorporating this technique in the surveillance protocol of ACC patients 
following complete tumor removal has been provided. However, some expert centers add FDG 
PET/CT at six-month intervals in the follow-up strategy (16). 
In the present study, we have assessed retrospectively our experience at the San Luigi Hospital 
where FDG PET/CT has been used as a second-line test in patients with a potential ACC recurrence 
found by CT during post-surgical follow-up. Therefore, we did not make a formal comparison of 
FDG PET/CT vs. CT to categorize patients as with or without ACC recurrence, but we assessed 
whether addition of FDG PET/CT in selected cases may refine diagnosis of ACC recurrence and 
inform the management strategy. To this aim, we have compared the results of either FDG PET/CT 
or CT with a gold standard confirmation of recurrence (positive histopathology report of 
removed/biopsied lesions or radiological progression of target lesions at follow-up) to assess the 
diagnostic performance of both techniques at different body sites to correctly categorize presumed 
ACC recurrences.  
Sensitivity of CT was overall greater than that of FDG PET/CT, and this may be partly expected 
due the specific inclusion criteria of the study requiring positivity of the CT scan (detection of new 
lesion(s) during follow-up). Sensitivity of CT was significantly greater than that of FDG PET/CT in 
the lungs and liver. The low sensitivity of FDG-PET for lung metastases is already known due 
to the limited FDG-PET/CT resolution of lung nodules less than 5 mm (9). In our series, many 
lung metastases were small and frequently located in the inferior lobes, close to the lung bases, 
where nodules are less detectable due to respiratory movements, compared to nodules in the 
upper parts of the lung (19).   
Specificity of FDG PET/CT was overall greater than that of CT, and the difference was at the 
limits of statistical significance in the liver. Moreover, FDG PET/CT had a greater LR+ than CT to 
identify liver and abdominal ACC recurrences. Thus, FDG PET/CT was of particular value in ruling 
out suspected ACC recurrences found by CT. FDG PET/CT findings informed patient management 
in 12 cases (21.1%) and the chosen strategy proved to be correct in all but one. In additional 4 
patients with discordant findings between the two techniques, all sites of pathological uptake by 
FDG PET/CT without a correspondent anatomical lesion at CT were finally demonstrated to be true 
ACC recurrences. Results of FDG PET/CT were not considered to guide management in such 
patients, but the choice proved to be a mistake. 
Strengths of the study are the rather large series considering the rarity of ACC, the central review 
of radiological material with FDG PET/CT scans done in a single center and the completeness of 
follow-up with unequivocal demonstration of recurrence, while we have to disclose the limit of a 
retrospective analysis and lack of standardization of the time interval elapsed between index 
CT and FDG PET/CT scan. There are no formal recommendations on the optimal time 
interval between the two imaging procedures, and in previous work a time interval within 3 
months was considered as acceptable (20). However, we should strive to achieve PET within 
one month from CT due to the possibility of fast disease progression. This seems a plausible 
compromise between the need of the shortest delay possible and the need to face practical 
problems (i.e. PET availability, travel arrangement for patients living far from the referral 
center). 
Although retrospective assessment of a decision making process may be partly flawed, the study 
findings are of clinical relevance showing that the use of FDG PET/CT to confirm anatomical 
lesions suspected to be ACC recurrences may allow a better selection of patients to surgery. Due to 
the limited efficacy of available medical treatments, surgical treatment of ACC recurrences still 
represents the best option to prolong patient survival whenever surgery can be done with radical 
intent, and proven that recurrence-free survival from primary surgery be of at least one year (21). 
FDG PET/CT was useful in differentiating liver nodular hyperplasia and post-surgery abdominal 
inflammatory reactions from ACC recurrence. As a matter of fact, FDG PET/CT pathological 
uptake of a liver or abdominal lesion increases by 38 or 52 times, respectively, the probability of a 
target lesion of being a true ACC recurrence.  
To conclude, we have showed that use of FDG PET/CT as a second-line test in the post-
operative surveillance of ACC patients following CT finding of a potential recurrence may have a 
significant impact on patient management, in particular for an appropriate selection of patients to 
surgery. Therefore, we suggest that FDG PET/CT becomes part of the post-operative work-up 
protocol of ACC patients following a CT scan that has identified morphological lesions 
compatible with ACC recurrences. Despite limited availability of the technique and cost issues, 
this strategy seems particularly appealing also with the aim of reducing the psychological burden of 
repeated testing in such patients. It remains to be demonstrated whether the routine use of FDG 
PET/CT in addition to cross-sectional imaging in the post-operative follow-up of ACC patients may 
improve detection and, more importantly, treatment of recurrent disease. 
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LEGENDS 
 
Figure 1. Discordant results between CT and FDG-PET/CT scans: patients with a greater 
number of target lesions in CT than in FDG-PET/CT scans are identified as CT > 
PET/CT; patients with a greater number of target lesions in FDG-PET/CT than CT scans 
are identified as PET/CT > CT; patients with CT and FDG-PET/CT scans showing target 
lesions in different districts are identified as CT ≠ PET/CT. Analysis is done per site of 
lesion. 
 
 
 
 
 
 
 
 
 
 
 
 
